Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 73 of 116

  1. TRU-016 and bendamustine

    Aptevo Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule completed

    1 trial
  2. TRUQAP 200 mg film-coated tablets, TRUQAP 160 mg film-coated tablets

    AstraZeneca AB

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial
  3. TS-1 with cisplatin

    Hospital Authority, Hong Kong

    Recurrent Gastric Cancer

    phase 2 small molecule active

    1 trial
  4. TTI-101

    Tvardi Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial
  5. TTI-101

    Tvardi Therapeutics

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial
  6. TTX-MC138

    Transcode Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial
  7. TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets

    Ningbo Cancer Hospital

    Non-resectable locally advanced or metastatic HER2-positive breast cancer

    phase 2 small molecule active

    1 trial
  8. TYRA-300

    Tyra Biosciences

    Locally Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial
  9. Tabelecleucel

    Evidence Based Cataract Study Group

    Nasopharyngeal Carcinoma

    phase 2 mab terminated

    1 trial
  10. Tagraxofusp

    Stemline Therapeutics B.V.

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial
  11. Tak-228 & Tak-117

    Takeda

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial
  12. Talazoparib Tosylate

    BioMarin Pharmaceutical Australia Pty Ltd

    Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial
  13. Tarlatamab

    Amgen

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  14. Tarlatamab, TARLATAMAB, Tarlatamab, SILTUXIMAB

    Amgen

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  15. Tarlatamab, Tarlatamab

    The George Institute

    Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)

    phase 2 small molecule active

    1 trial
  16. Tarlatamab, Tarlatamab

    Partner Therapeutics Limited

    Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2

    phase 2 small molecule active

    1 trial
  17. Tas-102(Suyuan) combined with bevacizumab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule active

    1 trial
  18. Tasigna 150 mg hard capsules, Scemblix 40 mg film-coated tablets

    Fondazione Telethon ETS

    BCR-ABL1+ Chronic Myeloid Leukemia

    phase 2 small molecule active

    1 trial
  19. Taxotere

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule terminated

    1 trial
  20. Tazemetostat

    Eisai Co.,

    Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial
  21. Tecentriq 1 200 mg concentrate for solution for infusion

    Tour Hekla

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial
  22. Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Locally advanced cervical cancer

    phase 2 small molecule active

    1 trial
  23. Tecentriq 1 200 mg concentrate for solution for infusion

    Wuhan Createrna Science and Technology Co., Ltd

    Limited disease small-cell lung cancer

    phase 2 small molecule active

    1 trial
  24. Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    (Diffuse) Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial
  25. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial
  26. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Patients with resectable hepatocellular carcinoma (amenable R0 resection) at high risk of recurrence.

    phase 2 small molecule active

    1 trial
  27. Tecentriq 1 200 mg concentrate for solution for infusion, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    The George Institute

    Adult participants with metastatic (advanced) solid tumors.

    phase 2 small molecule active

    1 trial
  28. Tecentriq 1 200 mg concentrate for solution for infusion, OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion., CAPECITABINE VIATRIS 500 mg, comprimé pelliculé

    CERO THERAPEUTICS HOLDINGS, INC.

    microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis

    phase 2 small molecule active

    1 trial
  29. Tecentriq 1 200 mg concentrate for solution for infusion, Pulmocis 2 mg trousse pour préparation radiopharmaceutique, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Non resectable Hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial
  30. Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Disc Medicine

    Squamous cell carcinoma of the anal canal

    phase 2 small molecule active

    1 trial
  31. Tecentriq 1,200 mg concentrate for solution for infusion, EXL01, IMFINZI 50 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion, IMJUDO 20 mg/ml concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial
  32. Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial
  33. Tecentriq 840 mg concentrate for solution for infusion, Tiragolumab

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial
  34. Tegafur Gimeracil Oteracil Potassium Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 small molecule active

    1 trial
  35. Telehealth Intervention

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 2 other active

    1 trial
  36. Telisotuzumab Vedotin

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  37. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial
  38. Temsirolimus

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial
  39. Teniposide administration

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial
  40. Tepotinib

    Serono Europe Limited

    Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification

    phase 2 small molecule active

    1 trial
  41. Tepotinib

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial
  42. Testosterone Enanthate 100 MG/ML Injectable Solution

    Hospital Authority, Hong Kong

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial
  43. Testosterone cypionate

    United Therapeutics Europe Ltd

    Castration Resistant Metastatic Prostate Cancer

    phase 2 small molecule completed

    1 trial
  44. Teverelix TFA

    Nordic Bioscience A/S

    Advanced prostate cancer

    phase 2 small molecule active

    1 trial
  45. Tevimbra 100 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.

    phase 2 small molecule active

    1 trial
  46. Tevimbra 100 mg concentrate for solution for infusion, Carboplatino Hikma 10 mg/ml soluzione per infusione, Cisplatino Hikma 1mg/ml concentrato per soluzione per infusione, Paclitaxel Accord Healthcare Italia 6 mg/ml, concentrato per soluzione per infusione, Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial
  47. Thalidomide and methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-LGL Leukemia

    phase 2 small molecule active

    1 trial
  48. The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs